Pelthos Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Pelthos Therapeutics Inc. (PTHS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 78.54 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-13
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 63.88K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 14.66K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 21.98K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 9.92K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 31.90K shares, a 2768.53% increase from fiscal 2024.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 1.11K shares, a 89.99% decline from fiscal 2023.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 11.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 63.88K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | 78.54K shares 10-Q · filed 2026-08-13 | 100.51K shares derived: sum of 3 quarters · filed 2026-08-13 | 110.44K shares derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | 14.66K shares 10-Q/A · filed 2026-08-13 | 36.64K shares derived: sum of 2 quarters · filed 2026-08-13 | 46.56K shares derived: sum of 3 quarters · filed 2026-08-13 | 46.56K shares derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | 21.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 31.90K shares derived: sum of 2 quarters · filed 2026-03-19 | 31.90K shares derived: sum of 3 quarters · filed 2026-08-13 | 31.90K shares 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 9.92K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 9.92K shares derived: sum of 2 quarters · filed 2026-08-13 | 9.92K shares 10-Q · filed 2025-11-13 | 9.92K shares derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | 0.00 shares 10-Q · filed 2026-08-13 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | 0.00 shares 10-Q/A · filed 2026-08-13 | 0.00 shares derived: sum of 2 quarters · filed 2026-08-13 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-13 | ||||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-19 | 1.11K shares 10-K · filed 2026-03-19 | 11.11K shares 10-K · filed 2025-03-27 | |||
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 1.11K shares 10-Q · filed 2025-11-13 | 11.11K shares 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | 1.11K shares 10-Q · filed 2025-08-13 | 11.11K shares 10-Q · filed 2024-08-13 | |||||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-27 | 11.11K shares 10-K · filed 2025-03-27 | 11.11K shares 10-K · filed 2024-04-16 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 11.11K shares 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | 11.11K shares 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |